Solid Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$207.1MTTM through 30 Jun 2026
Free Cash Flow -$187.8MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-55.4%ROE
-49.2%ROA
Balance Sheet Health
Current Ratio13.82x
Cash & Equivalents$159.4M
Quality Metrics
Altman Z-Score8.16
Piotroski F-Score2 / 9
Earnings-Beat Rate33.3%
Multi-Year Trend
RevenueFY2022: $8.1M
Dividend
No dividend
Capital Allocation
R&D Spend$167.4M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.